Biodegradable tube implants in experimental glaucoma surgery in the rabbit

Area of Science:

• Ophthalmology
• Biomaterials Science
• Drug Delivery

Background:

• Ocular drainage implants aim to reduce intraocular pressure (IOP) but often fail due to excessive scar tissue formation.
• Biocompatible materials are used to minimize foreign-body reactions, yet inflammation and fibrosis remain challenges.

Purpose of the Study:

• To evaluate poly(D, L-lactide-co-glycolide) copolymer as a biodegradable material for tubular ocular implants.
• To assess the efficacy of retinoic acid impregnation in mitigating inflammatory responses and enhancing implant performance.
• To determine the duration and magnitude of IOP reduction achieved with these prototype implants.

Main Methods:

• Investigated the inflammatory response to subconjunctivally and anterior chamber-placed poly(D, L-lactide-co-glycolide) copolymer particles, both plain and impregnated with retinoic acid.
• Utilized tubular implants made from the copolymer in operated eyes to measure IOP reduction over time compared to control eyes.
• Monitored inflammatory reactions and connective tissue formation for 60 days post-implantation.

Main Results:

• Retinoic acid-impregnated polymer particles elicited a milder initial inflammatory reaction and resulted in thinner connective tissue layers compared to plain polymer particles after 60 days.
• In the anterior chamber, both plain and retinoid-impregnated polymers showed milder inflammatory responses than when placed subconjunctivally.
• Tubular implants significantly reduced IOP in operated eyes for 9 weeks; retinoid-impregnated implants maintained significantly lower IOP for up to 7 weeks compared to plain implants.
• Retinoic acid impregnation did not prolong the overall effective functioning time of the implants.

Conclusions:

• Poly(D, L-lactide-co-glycolide) copolymer is a suitable biodegradable material for ocular implants, offering significant IOP reduction.
• Retinoic acid can modulate the inflammatory response to these implants, though it does not extend their functional duration.
• Further research may be needed to optimize drug-eluting strategies for sustained IOP control in glaucoma management.